-
New Immunotherapy Evidence for Chinese HCC Presented at ESMO Asia 2025
At the 2025 ESMO Asia Congress, Professor George K.K. Lau, Chairman of Humanity & Health Medical Group, Hong Kong, presented for the first time data from a Chinese population study…
-
Professor Jiayi Chen: Radiotherapy Combined With Systemic Therapy—A New Pathway for Advancing Treatment of Breast Cancer Brain Metastases
丨 9th East China Breast Cancer Salon** 01 Oncology Frontier: The prognosis for patients with breast cancer brain metastases remains suboptimal. What opportunities and challenges exist in combining radiotherapy with…
-
17th Shanghai Breast Reconstruction Conference
Professor Benlong Yang: Advancing Personalized Breast Reconstruction Through Innovative Techniques and Global Collaboration** 01 Oncology Frontier: Your lecture focused on “Frontier Choices in Breast Reconstruction Techniques.” For Chinese patients today,…
-
Prof. Liu Zhenzhen: How Dual Engines and Quality-Control Alliances Are Shaping Standardized Breast Cancer Care
Editor’s note: Breast cancer has become one of the leading malignancies threatening women’s health. Standardized diagnosis and treatment, together with rigorous quality control, are essential for improving survival outcomes and…
-
ESMO China–International Dialogue | Meeting at the Summit: How China’s Innovative ADCs sac-TMT and A166 Are Reshaping the Breast Cancer Treatment Landscape
At the 2025 European Society for Medical Oncology (ESMO) Annual Congress, Chinese innovative drugs and clinical research drew global attention. During the meeting, Xichun Hu, Professor at Fudan University Shanghai Cancer Center, presented a Late-Breaking Abstract (LBA) detailing the pivotal phase III study in which China’s first original HER2-targeted antibody–drug conjugate (ADC), A166 (budotituzumab vedotin), successfully challenged T-DM1 in the second-line setting for HER2-positive breast cancer. Based on this study, A166 received approval from the National Medical Products Administration (NMPA) on October 17, 2025, bringing a new standard-of-care option to clinical practice.
-
World Hepatitis Day 2025 | Prof. George Lau: Exploring Optimal Strategies for HBV Antiviral Therapy from an Economic Perspective
At the 2025 World Hepatitis Day Campaign Conference and the 7th Academic Conference on Clinical Cure of Chronic Hepatitis B, hosted by the China Foundation for Hepatitis Prevention and Control, Professor George Lau, Chairman of Hong Kong’s Humanity Medical Group and Chief Physician at Zhongshan Hospital affiliated with Fudan University, shared insights on the most…
-
APASL 2025 Expert Interview | Prof. George Lau: Dilemmas and Breakthroughs in Clinical Cure of Chronic Hepatitis B and Liver Cancer Prevention
At the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025), Professor George Lau, Chairman of Hong Kong Humanity Medical Group and Director of Humanity Medical Clinical Research Center, shared important insights on cuttingedge topics including clinical cure of chronic hepatitis B (CHB) and liver cancer prevention. With…
Connecting Medical Expertise through Media